CN1278731C - Compound bupleurum root medicinal preparation - Google Patents

Compound bupleurum root medicinal preparation Download PDF

Info

Publication number
CN1278731C
CN1278731C CN 200410065122 CN200410065122A CN1278731C CN 1278731 C CN1278731 C CN 1278731C CN 200410065122 CN200410065122 CN 200410065122 CN 200410065122 A CN200410065122 A CN 200410065122A CN 1278731 C CN1278731 C CN 1278731C
Authority
CN
China
Prior art keywords
bupleurum root
medicinal preparation
preparation according
root medicinal
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN 200410065122
Other languages
Chinese (zh)
Other versions
CN1634330A (en
Inventor
阎政
米靖宇
刘志祥
王金陵
杨南林
李纯球
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Wuzhong Medical Group Co.,Ltd.
Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. Suzhou pharmaceutical factory
Original Assignee
Wuzhong Chinese Medicines Research & Development Co Ltd Jiangsu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuzhong Chinese Medicines Research & Development Co Ltd Jiangsu filed Critical Wuzhong Chinese Medicines Research & Development Co Ltd Jiangsu
Priority to CN 200410065122 priority Critical patent/CN1278731C/en
Publication of CN1634330A publication Critical patent/CN1634330A/en
Application granted granted Critical
Publication of CN1278731C publication Critical patent/CN1278731C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a compound bupleurum root soft capsule oral medicine preparation. The medicine contains bupleurum root extract, zedoary turmeric oil and weeping forsythia extract. The medicine preparation comprises tablets, hard capsules, soft capsules, dripping pills, oral liquid and injections. The compound bupleurum root soft capsule oral medicine preparation has the advantages that the compound bupleurum root soft capsule oral medicine preparation is a patent medicine with a new prescription, and compared with other pure Chinese medicine varieties sold on the market, the compound bupleurum root soft capsule oral medicine preparation has the functions for resisting viruses, resisting bacteria, clearing heat and relieving pain, and has complete functions. The compound bupleurum root soft capsule oral medicine preparation does not contain western medicine ingredients, especially does not contain antibiotics, and can avoid side effects due to the excess use of antibiotics.

Description

Compound bupleurum root medicinal preparation
Technical field
The present invention relates to a kind of Chinese medicine, be specifically related to a kind of compound bupleurum root medicinal preparation, be mainly used in the treatment of upper respiratory tract infection etc. with antiviral, antiinflammatory and antipyretic effect.
Background technology
The cause of disease of flu is comparatively complicated, and the common cold treatment medicine of Xiao Shouing has kind more than 50 in the market, adds different with medicine different name and various dosage forms always to have the medicine that the treatment of kind more than 100 is caught a cold.The medication of traditional treatment flu, doctor's more options antiviral drugs and ntipyretic analgesic medicine are main.Along with the hospitalize development of technology, it is found that the compound preparation of forming by ntipyretic analgesic medicine and antiviral drugs, common cold treatment is had more specific aim, better efficacy.
Recently, investigation shows to the use of coldrex tendency in professional institution, and the compound prescription of being made up of antipyretic analgesic and antiviral agents as " KUAIKE " etc., becomes doctors' at first medicine, and selection rate is up to 48%.The selection purpose of common cold treatment medicine has shown the transformation of current clinical treatment flu disease on method.Shown that doctors more and more tend to the new approaches of the symptomatic treatment of working along both lines from antipyretic-antalgic and antiviral two aspects.
Radix Bupleuri all has the trivial solution heat effect to the heating that multiple reason causes.At anti-virus aspect, Radix Bupleuri removes the inhibition hemophilus influenza, Diplococcus pneumoniae, outside the bacterium effect of golden yellow Portugal, to escherichia coli, bacillus pyocyaneus, dysentery bacterium also have strong inhibitory action, so Radix Bupleuri not only can be applied to treat influenza, the multiple infectious diseases such as caused various infection mumps, pneumonia, acute bronchitis of catching a cold all there is therapeutical effect.
Radix Bupleuri is used for the treatment of flu the beginning sees Shennong's Herbal, all on the books from Qin Han to the medical science works in bright clear each period.In recent years, many scholars have done a large amount of research work to Radix Bupleuri, and have obtained gratifying achievement, prove that Radix Bupleuri can alleviate cold symptoms comprehensively.Summary is got up, and Radix Bupleuri has following five effects greatly: 1) refrigeration function; 2) antibiosis and antiviral functions; 3) analgesic activity; 4) antitussive effect; 5) immune dual regulation.
Rhizoma Curcumae is zingiberaceous plant Rhizoma Curcumae, Radix Curcumae or Guangxi zedoary rhizome.Acrid in the mouth, hardship, warm in nature have the effect of circulation of qi promoting removing blood stasis with potent drugs, removing food stagnancy pain relieving.Diseases such as the stagnant distending pain of main clinically treatment, abdominal pain due to blood stasis, hepatosplenomegaly, amenorrhea due to stagnation of blood, traumatic injury.Modern study, the chemical constituent of Rhizoma Curcumae mainly contains volatile oil, and its composition is Rhizoma Curcumae furan alkene copper, Borneolum Syntheticum, curcumenol etc.Oleum Curcumae has the effect of promoting flow of QI and blood, removing food stagnancy pain relieving, blood circulation promoting and blood stasis dispelling, removing the necrotic tissue and promoting granulation, enhancing human body immunity ability.Modern pharmacological research shows: Oleum Curcumae has: 1) antibacterial action; 2) antiinflammatory action; 3) antivirus action.The antiviral drugs that with the Oleum Curcumae is main component at present is extensive use of clinically.
Fructus Forsythiae is the fruit of Oleaceae plant Fructus Forsythiae, has that heat-clearing and toxic substances removing, removing heat from blood purge heat, the function of dispersing swelling and dissipating binds.Be mainly used in febricity body constitution and interior-heat syndrome.The traditional Chinese medical science is thought, its cold nature, bitter in the mouth, the function heat-clearing and toxic substances removing, mass dissipating and swelling eliminating, be applicable to warm, erysipelas, macule, carbuncle and ulcer toxic swelling and anaphylactoid purpura etc." herbal classic ": " main cold and heat, scrofula, scrofula, carbuncle, malignant boil, goiter, stagnation of pathogenic heat, diseases due to noxious agents produced by various parasites." " Japan hanako materia medica ": " control the furuncle pain relieving." " pearl sac ": " usefulness of Fructus Forsythiae has three: removing pathogen in the heart is through exopathogenic heat, and one also; Go all heat of the part of the body cavity above the diaphragm housing the heart and lungs, two also; Be persons particularly liable to develop skin infection's panacea, three also.”
Fructus Forsythiae contains triterpenoid saponin, and peel contains sterol, phenolic constituent (forsythol), alkaloid, Saponin, oleanolic acid, Coumarins, also has abundant Citrin and a small amount of volatile oil.Fructus Forsythiae has broad-spectrum antibacterial action, and staphylococcus aureus, Hayes dysentery bacterium are had very strong inhibitory action, and other pathogenic bacterium, influenza virus, fungus are all had certain inhibitory action, and contained forsythol is main antipathogenic composition; Antiinflammatory action is arranged; The contained oleanolic acid of Fructus Forsythiae has heart tonifying, diuresis and hypotensive activity; Citrin can reduce vascular permeability and fragility, prevents haemolysis.Decoct has town's effect of telling, anti-liver injury effect.Modern pharmacological research shows that Fructus Forsythiae has: 1) antibacterial action; 2) antiinflammatory action; 3) the refrigeration function decoct that experiment showed, Fructus Forsythiae has refrigeration function to the rabbit of artificial fever.
Comprehensive above-mentioned situation, Radix Bupleuri all has the trivial solution heat effect to the heating that multiple reason causes.The material base of Radix Bupleuri refrigeration function is saikoside and volatile oil, has refrigeration function, antibiosis and antiviral functions, analgesic activity, antitussive effect, immune dual regulation; The chemical constituent of Rhizoma Curcumae mainly contains volatile oil, and Oleum Curcumae has: antibacterial action, antiinflammatory action, antivirus action; Be rich in forsythol, oleanolic acid, Citrin in the Fructus Forsythiae, have: effects such as antibacterial action, antiinflammatory action, refrigeration function, reduction vascular permeability.
Summary of the invention
The object of the present invention is to provide a kind of compound bupleurum root medicinal preparation, be used for the treatment of flu, influenza particularly demonstrates fully the therapeutical effect of prescription in the flu of antipyretic-antalgic, antibiotic, antiinflammatory, anti-virus aspect.
Technical scheme of the present invention is: a kind of compound bupleurum root medicinal preparation, it comprises Radix Bupleuri, Fructus Forsythiae, Rhizoma Curcumae.
Radix Bupleuri in the described medicine is the extract from the Radix Bupleuri that feeds intake in proportion, described Fructus Forsythiae is the extract from the Fructus Forsythiae that feeds intake in proportion, the Oleum Curcumae of described Rhizoma Curcumae for extracting from the Rhizoma Curcumae that feeds intake in proportion, the weight ratio that feeds intake of described raw material is a Radix Bupleuri: Fructus Forsythiae: Rhizoma Curcumae=1: 2~4: 1.5~3.
Described compound bupleurum root medicinal preparation comprises tablet, hard capsule, soft capsule, granule, drop pill, oral liquid and injection.
Oleum Curcumae has antivirus action, and Radix Bupleuri has antipyretic effect, and Fructus Forsythiae has antiinflammatory action.Three's 5 usefulness are used for the treatment of viral influenza and bacillary flu, and it is viral or bacillary not needing dialectical differentiation flu, and can prevent concurrent bacterial infection of viral influenza later stage.Owing to being pure Chinese medicinal preparation thereby having avoided antibiotic use, especially infantile common cold is suitable for the fever symptom.
The present invention compared with prior art has following advantage:
1, do not contain western medicine composition, especially do not contain antibiotic, can avoid antibiotic too much to use and the side effect of generation.
2 compare with other pure herbal species that gone on the market, have antiviral, antibiotic and antipyretic effect simultaneously, and effect comprehensively.
3, to carry out with the mice be the pharmacodynamics test of object in the present invention, and proving has tangible antipyretic effect to the caused fever of viral influenza, and antibiotic, disease-resistant degree effect is remarkable.
The specific embodiment
A kind of compound bupleurum root medicinal preparation, it comprises Radix Bupleuri, Fructus Forsythiae, Rhizoma Curcumae.
Radix Bupleuri in the described medicine is the extract of the Radix Bupleuri that feeds intake in proportion, described Fructus Forsythiae is the extract of the Fructus Forsythiae that feeds intake in proportion, the Oleum Curcumae of described Rhizoma Curcumae for extracting from the Rhizoma Curcumae that feeds intake in proportion, the weight ratio that feeds intake of the above-mentioned raw material that feeds intake in proportion is a Radix Bupleuri: Fructus Forsythiae: Rhizoma Curcumae=1: 2~4: 1.5~3.
Described Oleum Curcumae is that supercritical CO 2 extraction or steam distillation extract volatile oil.Described Oleum Curcumae is meant the Oleum Curcumae clathrate in tablet, hard capsule, granule, drop pill, comprise Benexate Hydrochloride and hydroxypropyl clathrate.A kind of detailed process of clathrate preparation is as follows: adopt the saturated aqueous solution envelope, Oleum Curcumae: beta-schardinger dextrin-: the proportioning of water is 1mL: 4g: 60mL, and mixing time is 2 hours, obtains the Oleum Curcumae Benexate Hydrochloride.
The extract of Radix Bupleuri extracts according to a conventional method, mainly be medical material with 40~85% ethanol extractions, the medicinal residues decocting is boiled carry out water extraction again, the mixed Radix Bupleuri extract that is of water extract and ethanol extraction.A kind of detailed process wherein is as follows: medical material is with 60% ethanol extraction, extracting solution concentrates, and drying obtains ethanol extraction, and medicinal residues decoct with water secondary, 1 hour for the first time, 45 minutes for the second time, to filter, filtrate merging is evaporated to proportion 1.15~1.20, ethanol precipitate with ethanol with triplication, supernatant concentration is also dry, obtains water extract, the mixed Radix Bupleuri extract that promptly gets of ethanol extraction and water extract.The extract of Fructus Forsythiae extracts according to a conventional method, mainly be medical material with 40~85% ethanol extractions, the medicinal residues decocting boil water extract, the mixed Fructus Forsythiae extract that is of water extract and alcohol extract.A kind of detailed process wherein is as follows: medical material is with 65% ethanol extraction, extracting solution concentrates, drying obtains ethanol extraction, and medicinal residues decoct with water secondary, each 1 hour, filter, filtrate merging is evaporated to proportion 1.15~1.20, and with the ethanol precipitate with ethanol of triplication, supernatant concentration is also dry, obtain water extract, the mixed Fructus Forsythiae extract that promptly gets of ethanol extraction and water extract.
Can make the several formulations type after above Radix Bupleuri extract, Fructus Forsythiae extract and Oleum Curcumae are mixed, comprise that described medicine is an oral administered dosage form, described oral administered dosage form is an oral solid formulation, comprise tablet, soft capsule, hard capsule, granule, drop pill, described oral administered dosage form is an oral liquid, also can be to make injection.
Also comprise excipient in the medicine of described tablet, after described Radix Bupleuri, Fructus Forsythiae, Rhizoma Curcumae and excipient are mixed, be pressed into tablet.
Described excipient is one or more the mixture in wetting agent, binding agent, disintegrating agent, the lubricant.
Wetting agent and binding agent are a kind of or its mixture in distilled water, ethanol, starch slurry, syrup, the refined honey.Disintegrating agent is one or more the mixture in starch, modified starch, cellulose, alginic acid, plant gum, kaolin, aluminium-magnesium silicate, the Bentonite.Lubricant is a kind of or wherein several mixture of stearic acid, calcium stearate, magnesium stearate, zinc stearate, hydrogenated vegetable oil, polyoxyethylene monostearate, light mineral oil, liquid Paraffin, wax apoplexy due to endogenous wind.
After making hard capsule, described medicine is packed in the hard capsule case.
After making soft capsule, also include stabilizing agent and solvent in the described medicine.Described stabilizing agent is a kind of or its mixture in water, glycerol, tween, ethyoxyl castor oil hydrogenated, soybean lecithin, Cera Flava, glyceryl monostearate, ethyl cellulose, solid polyethylene glycol, the PEG400 glyceryl monostearate.
Described solvent is a kind of or its mixture in liquid polyethylene glycol, isopropyl alcohol, tween, span, glycerol, propylene glycol, water, the vegetable oil.
The weight proportion of described medicine is as follows:
The mixture 1 of Radix Bupleuri extract, Fructus Forsythiae extract, Oleum Curcumae
Solvent 1~4
Stabilizing agent 0.01~1.20
Above-mentioned medicine is filled in the softgel shell, makes Oleum Curcumae can not volatilize, and keeps the active ingredient of medicine.
After making granule, also include excipient in the described granule, after described Radix Bupleuri, Fructus Forsythiae, Rhizoma Curcumae and excipient are mixed, make graininess.
Described excipient is one or more in wetting agent, binding agent, the disintegrating agent.
Described wetting agent and binding agent are a kind of or its mixture in distilled water, ethanol, starch slurry, syrup, the refined honey; Described disintegrating agent is a kind of or its mixture in starch, modified starch, cellulose, alginic acid, plant gum, kaolin, aluminium-magnesium silicate, the Bentonite.
After making drop pill, also comprise substrate in the described medicine, described substrate be below 40 ℃ for medicinal substrate stationary state, that can form drop pill, be one or more the mixture in solid polyethylene glycol, polyoxyethylene (40) stearate, poloxamer, carbamide, monostearate, octadecanol, hexadecanol, glyceryl monostearate, the tween.
Oral administered dosage form is an oral liquid, can make oral liquid, also comprises a kind of or its mixture in cosolvent, correctives, the aromatic in the described medicine.
In tablet, hard capsule, granule, drop pill, described Rhizoma Curcumae is meant the Oleum Curcumae clathrate, and described Oleum Curcumae clathrate comprises Benexate Hydrochloride, hydroxypropyl clathrate.
After making injection, also comprise a kind of or its mixture in mixed solvent, the injection non-ionic solubilizer in the described medicine, described mixed solvent comprises water, ethanol, also comprise the mixture of low carbon polyol or Polyethylene Glycol or low carbon polyol and Polyethylene Glycol, described low carbon polyol is meant the mixture of propylene glycol or glycerol or propylene glycol and glycerol; The consumption of described mixed solvent should be enough to make described medicine dissolution and keep stable.Described injection non-ionic solubilizer is one of polyoxyethylene monostearate, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil or its mixture.
Good effect of the present invention has provided a kind of compound bupleurum root medicinal preparation, product is new prescription patent medicine, Oleum Curcumae has antivirus action, Radix Bupleuri has the analgesic effect of bringing down a fever, Fructus Forsythiae has antibacterial action, and three's 5 usefulness are compared with other pure herbal species that gone on the market, have antiviral, antibiotic and antipyretic effect simultaneously, effect comprehensively.And do not contain western medicine composition, especially do not contain antibiotic, can avoid antibiotic too much to use and the side effect of generation.
Embodiment 1: weight ratio (gram/sheet)
Radix Bupleuri extract 0.09
The Fructus Forsythiae extract corresponding amount
Oleum Curcumae clathrate corresponding amount
Starch is an amount of
Hydroxypropyl cellulose 0.09
Method for making: Oleum Curcumae clathrate and Radix Bupleuri extract, Fructus Forsythiae extract, hydroxypropyl cellulose, starch are mixed evenly, add suitable quantity of water, the system soft material is granulated, and is pressed into the compound bupleuri sheet at last.
Embodiment 2: weight ratio (gram/grain)
Radix Bupleuri extract 0.04
The Fructus Forsythiae extract corresponding amount
Oleum Curcumae clathrate corresponding amount
Starch is an amount of
Microcrystalline Cellulose 0.05
Method for making: Oleum Curcumae clathrate and Radix Bupleuri extract, Fructus Forsythiae extract, microcrystalline Cellulose, starch are mixed evenly, add an amount of water system soft material, granulate, oven dry, granulate pours in the hard capsule case, makes the compound bupleuri hard capsule.
Embodiment 3:
Components by weight (gram/grain)
Radix Bupleuri extract 0.07
The Fructus Forsythiae extract corresponding amount
The Oleum Curcumae corresponding amount
Polyethylene Glycol 0.21
Glycerol 0.035
Capsule shells 0.20
Method for making: extract, the Fructus Forsythiae extract of Radix Bupleuri are beaten powder cross behind 120~200 mesh sieves standby, earlier stabilizing agent and partial solvent heating for dissolving are formed the thermosol thing, again the thermosol thing is joined in the residual solvent that is preheated to 35~55 ℃ lentamente, the limit edged stirs, and adds the fully mixed rear packing of Radix Bupleuri extract, Fructus Forsythiae extract and the Oleum Curcumae pulverized then.Make the compound bupleuri soft capsule.
Embodiment 4: weight ratio (gram/bag)
Radix Bupleuri extract 0.98
The Fructus Forsythiae extract corresponding amount
Oleum Curcumae clathrate corresponding amount
Starch is an amount of
Hydroxypropyl methylcellulose 1.45
Method for making: Oleum Curcumae clathrate and Radix Bupleuri extract, Fructus Forsythiae extract, hydroxypropyl methylcellulose, starch is evenly mixed, add suitable quantity of water, the system soft material is granulated, last granulate, fill promptly gets the compound bupleuri granule in bag.
Embodiment 5:
Radix Bupleuri extract 0.01
The Fructus Forsythiae extract corresponding amount
Oleum Curcumae clathrate corresponding amount
Macrogol 4000 is an amount of
Method for making: taking polyethylene glycol 4000 is heated to molten condition, add Radix Bupleuri extract, Fructus Forsythiae extract in the Macrogol 4000 under molten condition again, continue heating, stir, heat-retaining condition adds the Oleum Curcumae clathrate down, splashes into after stirring and is condensed into ball in the liquid coolant.Make the compound bupleuri drop pill.
Embodiment 6:
Radix Bupleuri extract 0.12
The Fructus Forsythiae extract corresponding amount
The Oleum Curcumae corresponding amount
Tween 80 is an amount of
Propylene glycol 20ml
Correctives 0.1
Water is made 100ml
Method for making: Radix Bupleuri extract, Fructus Forsythiae extract, Oleum Curcumae mix, and add the mixed solvent of being made up of tween 80, propylene glycol, artificial essence and part water, stir and make into the solution shape, add water to full dose, filter, fill is in oral liquid bottle, the compound bupleuri oral liquid is made in sterilization.
Embodiment 7:
Radix Bupleuri extract 0.02
The Fructus Forsythiae extract corresponding amount
The Oleum Curcumae corresponding amount
Tween 80 is an amount of
Propylene glycol 20ml
Water is made 100ml
Method for making: Radix Bupleuri extract, Fructus Forsythiae extract, Oleum Curcumae mix, and add the mixed solvent of being made up of tween 80, propylene glycol and part water, stir and make into the solution shape, add water to full dose, filter, and fill is in ampoule, and the compound bupleuri injection is made in sterilization.
Described oral liquid is an oral liquid, also comprises a kind of or its mixture in cosolvent, correctives, the aromatic in the described oral liquid; Cosolvent is meant it is one of polyoxyethylene monostearate, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil or its mixture at least; Correctives is meant the material that can change the sense of taste, the taste that is usually used in covering the cacogeusia of medicine in the medicament and improves medicament; Aromatic is meant volatile oil or balm, synthetic spice or its mixture of contained volatile aromatic oil such as fruit, seed, flower, leaf, root, stem and skin after purifying of natural plants.

Claims (26)

1, a kind of compound bupleurum root medicinal preparation, it is characterized in that: the raw material for preparing its active ingredient is made up of Radix Bupleuri, Fructus Forsythiae, Rhizoma Curcumae, the Radix Bupleuri extract of Radix Bupleuri in the described medicine for from the Radix Bupleuri that feeds intake in proportion, extracting, the Fructus Forsythiae extract of described Fructus Forsythiae for from the Fructus Forsythiae that feeds intake in proportion, extracting, the Oleum Curcumae of described Rhizoma Curcumae for extracting from the Rhizoma Curcumae that feeds intake in proportion, the weight ratio that feeds intake of described each raw material is a Radix Bupleuri: Fructus Forsythiae: Rhizoma Curcumae=1: 2~4: 1.5~3.
2, compound bupleurum root medicinal preparation according to claim 1 is characterized in that: described pharmaceutical preparation is oral administered dosage form.
3, compound bupleurum root medicinal preparation according to claim 2 is characterized in that: described oral administered dosage form is an oral solid formulation.
4, compound bupleurum root medicinal preparation according to claim 2 is characterized in that: described oral solid formulation is at least one of tablet, hard capsule, soft capsule, granule, drop pill.
5, compound bupleurum root medicinal preparation according to claim 4 is characterized in that: also comprise excipient in the medicine of described tablet.
6, compound bupleurum root medicinal preparation according to claim 5 is characterized in that: after described Radix Bupleuri, Fructus Forsythiae, Rhizoma Curcumae and excipient are mixed, be pressed into tablet.
7, compound bupleurum root medicinal preparation according to claim 5 is characterized in that: described excipient is one or more the mixture in wetting agent, binding agent, disintegrating agent, the lubricant.
8, compound bupleurum root medicinal preparation according to claim 7 is characterized in that: described wetting agent and binding agent are one or more the mixture in distilled water, ethanol, starch slurry, syrup, the refined honey; Described disintegrating agent is one or more the mixture in starch, modified starch, cellulose, alginic acid, plant gum, kaolin, aluminium-magnesium silicate, the Bentonite; Described lubricant is a kind of or wherein several mixture of stearic acid, calcium stearate, magnesium stearate, zinc stearate, hydrogenated vegetable oil, polyoxyethylene monostearate, light mineral oil, liquid Paraffin, wax apoplexy due to endogenous wind.
9, compound bupleurum root medicinal preparation according to claim 4 is characterized in that: in described hard capsule, described medicine is filled in the hard capsule.
10, compound bupleurum root medicinal preparation according to claim 4 is characterized in that: also include stabilizing agent and solvent in the medicine of described soft capsule, and described medicine is loaded in the softgel shell.
11, compound bupleurum root medicinal preparation according to claim 10 is characterized in that: the weight proportion of described medicine is as follows;
The pro rata mixture 1 of Radix Bupleuri extract, Fructus Forsythiae extract, Oleum Curcumae
Solvent 1~4
Stabilizing agent 0.01~1.20
12, compound bupleurum root medicinal preparation according to claim 10 is characterized in that: described stabilizing agent is a kind of or its mixture in water, glycerol, tween, ethyoxyl castor oil hydrogenated, soybean lecithin, Cera Flava, glyceryl monostearate, ethyl cellulose, solid polyethylene glycol, the PEG400 glyceryl monostearate; Described solvent is a kind of or its mixture in liquid polyethylene glycol, isopropyl alcohol, tween, span, glycerol, propylene glycol, water, the vegetable oil.
13, compound bupleurum root medicinal preparation according to claim 4 is characterized in that: also include excipient in the described granule.
14, compound bupleurum root medicinal preparation according to claim 13 is characterized in that: after described Radix Bupleuri, Fructus Forsythiae, Rhizoma Curcumae and excipient are mixed, make graininess.
15, compound bupleurum root medicinal preparation according to claim 13 is characterized in that: described excipient is one or more in wetting agent, binding agent, the disintegrating agent.
16, compound bupleurum root medicinal preparation according to claim 15 is characterized in that: described wetting agent and binding agent are a kind of or its mixture in distilled water, ethanol, starch slurry, syrup, the refined honey; Described disintegrating agent is a kind of or its mixture in starch, modified starch, cellulose, alginic acid, plant gum, kaolin, aluminium-magnesium silicate, the Bentonite.
17, compound bupleurum root medicinal preparation according to claim 4 is characterized in that: also include substrate in the medicine of described drop pill.
18, compound bupleurum root medicinal preparation according to claim 17, it is characterized in that: described substrate is to be under the room temperature condition below 40 ℃ to be a kind of or its mixture in solid polyethylene glycol, polyoxyethylene (40) stearate, poloxamer, carbamide, monostearate, octadecanol, hexadecanol, glyceryl monostearate, the tween by medicinal substrate stationary state, that can form drop pill.
19, compound bupleurum root medicinal preparation according to claim 4 is characterized in that: in tablet, hard capsule, granule, drop pill, described Rhizoma Curcumae is meant the Oleum Curcumae clathrate.
20, compound bupleurum root medicinal preparation according to claim 19 is characterized in that: described Oleum Curcumae clathrate comprises Benexate Hydrochloride, hydroxypropyl clathrate.
21, compound bupleurum root medicinal preparation according to claim 2 is characterized in that: described oral administered dosage form is an oral liquid.
22, compound bupleurum root medicinal preparation according to claim 21 is characterized in that: described oral liquid is an oral liquid.
23, compound bupleurum root medicinal preparation according to claim 22 is characterized in that: also comprise a kind of or its mixture in cosolvent, correctives, the aromatic in the described oral liquid; Cosolvent is meant it is one of polyoxyethylene monostearate, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil or its mixture at least; Correctives is meant the material that can change the sense of taste, the taste that is usually used in covering the cacogeusia of medicine in the medicament and improves medicament; Aromatic is meant volatile oil or balm, synthetic spice or its mixture of contained volatile aromatic oil such as fruit, seed, flower, leaf, root, stem and skin after purifying of natural plants.
24, compound bupleurum root medicinal preparation according to claim 1 is characterized in that: described medicine is an injecting medicine-feeding form.
25, compound bupleurum root medicinal preparation according to claim 24 is characterized in that: also comprise a kind of or its mixture in mixed solvent, the injection non-ionic solubilizer in the described medicine.
26, compound bupleurum root medicinal preparation according to claim 25, it is characterized in that: described mixed solvent comprises water, ethanol, described mixed solvent also comprises low carbon polyol, one of Polyethylene Glycol or both mixture, described low carbon polyol is meant propylene glycol, the mixture of one of glycerol or propylene glycol and glycerol, the consumption of described mixed solvent should be enough to make and comprises Radix Bupleuri, Fructus Forsythiae, the medicine dissolution of Rhizoma Curcumae also keeps stable, and described injection non-ionic solubilizer is to be polyoxyethylene monostearate at least, polyoxyethylene sorbitan fatty acid ester, one of polyoxyethylene castor oil or its mixture.
CN 200410065122 2004-10-22 2004-10-22 Compound bupleurum root medicinal preparation Active CN1278731C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 200410065122 CN1278731C (en) 2004-10-22 2004-10-22 Compound bupleurum root medicinal preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 200410065122 CN1278731C (en) 2004-10-22 2004-10-22 Compound bupleurum root medicinal preparation

Publications (2)

Publication Number Publication Date
CN1634330A CN1634330A (en) 2005-07-06
CN1278731C true CN1278731C (en) 2006-10-11

Family

ID=34846441

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200410065122 Active CN1278731C (en) 2004-10-22 2004-10-22 Compound bupleurum root medicinal preparation

Country Status (1)

Country Link
CN (1) CN1278731C (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100444734C (en) * 2005-11-08 2008-12-24 广州暨南大学医药生物技术研究开发中心 A compound antivirus sprayer and preparation method thereof
CN100404064C (en) * 2006-03-02 2008-07-23 成都厚发科技开发有限公司 Medicine composition having functions of resisting virus and clearing heat and preparing method
CN113425694A (en) * 2021-07-02 2021-09-24 杭州蚕宝生物技术有限公司 Dendrobium alkaloid orally disintegrating tablet and preparation method thereof
CN117530917B (en) * 2024-01-09 2024-04-05 北京中科利华医药研究院有限公司 Bupleurum root suppository

Also Published As

Publication number Publication date
CN1634330A (en) 2005-07-06

Similar Documents

Publication Publication Date Title
CN102225138B (en) Traditional Chinese medicine composition for treating fracture and preparation method and application thereof
CN100350900C (en) Diphase capsule of compound dalbergia wood and preparation method
CN1278731C (en) Compound bupleurum root medicinal preparation
CN1698820A (en) Dripping pills with jaundice eliminating liver protecting functions and its preparation method
CN100350899C (en) Diphase capsule of red sage root for coronary heart disease and preparation method
CN100350898C (en) Diphase capsule of compound notoginseng and preparation method
CN1720948A (en) Dripping pills of lllicium henryi dripping pills and method for preparing the same
CN1879701A (en) Cold-treating medicine and preparation method thereof
CN1233401C (en) Agastache capsule for restoring healthy energy andits prepn and application
CN1814188A (en) Vitaminc lonicera and forsythia capsule and preparing method
CN1931279A (en) Medicine for treating biliary tract infection and its prepn process
CN1689637A (en) Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process
CN100375616C (en) Bone strengthening dripping pills with Premena fulva craib as raw material and method for preparing the same
CN100453073C (en) Compound radical lobelia dripping pill and its preparing method
CN100542517C (en) Calculus bovis detoxifying dropping pill and preparation method thereof
CN1748741A (en) Little leaf deervetch herb acne removing preparation and new preparing method
CN1682819A (en) Sihuang intense heat purging dripping pill and its preparing method
CN1260204A (en) Medicament for treating diabetes and its preparation method
CN1718225A (en) Compound traditional Chinese medicine for treating hepatic lesion, and its prepn. method
CN100348171C (en) Yujin drop pill for clearing away the heat-evil and expelling superficial evils and its preparation method
CN1840063A (en) Dripping pills of 'Da Yuan Yin' and preparation method thereof
CN1872219A (en) Soft capsule for treating headache, and preparation method
CN1720950A (en) Compound drop pills of Chinese angelica and its preparation method
CN1118278C (en) Application of ursolic acid in medicine for treating viral hepatitis
CN105106817A (en) Yao medicine compound broadleaf globethistle inflorescence tablet for treating diabetes and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: JIANGSU WUZHONG MEDICINE GROUP CO., LTD.

Free format text: FORMER OWNER: JIANGSU WUZHONG CHINESE MEDICINE RESEARCH AND DEVELOPMENT CO., LTD.

Effective date: 20091030

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20091030

Address after: 8, No. 2 Wu Dong South Road, Jiangsu, Suzhou

Patentee after: Jiangsu Wuzhong Medical Group Co.,Ltd.

Address before: No. 2, Soochow South Road, Jiangsu, Suzhou

Patentee before: Wuzhong Chinese Medicines Research & Development Co., Ltd., Jiangsu

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160918

Address after: 215168, No. 2, Soochow South Road, Suzhou, Jiangsu, 8

Patentee after: Jiangsu Wuzhong Medical Group Co.,Ltd.

Patentee after: Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. Suzhou pharmaceutical factory

Address before: 215168, No. 2, Soochow South Road, Suzhou, Jiangsu, 8

Patentee before: Jiangsu Wuzhong Medical Group Co.,Ltd.